| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/10/2002 | WO2002002564A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | WO2002002554A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | WO2001043691A3 Fragments and antagonists of heat shock protein 60 |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | US20020004510 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 01/10/2002 | US20020004501 Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders |
| 01/10/2002 | US20020004494 Muscular disorders, gastrointestinal disorders, respiratory system disorders |
| 01/10/2002 | US20020004492 Polypeptides; wound healing agent, antiinflammatory agent |
| 01/10/2002 | DE10031585A1 2-Aminoalkyl-thieno[2,3-d]pyrimidine 2-aminoalkyl-thieno [2,3-d] pyrimidines |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2413243A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2410953A1 Adenylyl and guanylyl cyclases |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169316A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169060A1 Sodium channel blocker compositions and the use thereof |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169040A2 Flupirtine in the treatment of fibromyalgia and related conditions |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP0702561B1 Treatment of neuromuscular disorders and conditions with botulinum serotyp e |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1329886A Medical percutaneous preparation containing hydrophilic or salt form |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000664A1 2-aminoalkyl-thieno[2,3-d]pyrimidines |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000245A1 Neurotoxic oligomers |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001045695A3 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002161 5-HT ligands used to treat central nervous system disorders |
| 01/03/2002 | US20020002156 Androgenic steroid compounds and a method of making and using the same |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413354A1 Neurotoxic a.beta. oligomers in alzheimer's disease |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/02/2002 | EP1166793A1 Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165101A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/02/2002 | EP1165081A1 Tolperison-containing, pharmaceutical preparation for oral administration |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | CN1329616A Acylated benzylmal tosides as inhibitors of smooth muscle cell proliferaton |
| 01/02/2002 | CN1329610A Chromenone and chromanone derivatives as integrin inhibitors |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 01/02/2002 | CN1329493A Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 01/02/2002 | CN1328848A Bimaxiancao capsule and its preparation method |
| 01/01/2002 | US6335354 Aminopyridines and methods of using thereof |
| 01/01/2002 | US6335333 Matrix metalloproteinase inhibitors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098262A1 Amidine derivatives as selective antagonists of nmda receptors |
| 12/27/2001 | WO2001097786A2 Benzothiazole derivatives |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | US20010056103 Non-immunosuppressive, piperidino or pyrrolidino amide derivative has an affinity for an FKBP-type immunophilin, useful for treating Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis |
| 12/27/2001 | US20010056077 Pharmaceutical composition for treatment of duchenne muscular dystrophy |
| 12/27/2001 | US20010055590 Method for enhancing myoblast migration and invasion in the context of gene therapy |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413418A1 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328566A Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 12/26/2001 | CN1328417A Compositions and methods for treatment of mitochondrial diseases |
| 12/26/2001 | CN1327799A Mixture of white pepper and borneol and its application |
| 12/25/2001 | US6333341 Tumor necrosis factor, antiinflammatory agents and analgesics |